Sensorion SA (ALSEN) - Total Liabilities

Latest as of June 2025: €16.36 Million EUR ≈ $19.13 Million USD

Based on the latest financial reports, Sensorion SA (ALSEN) has total liabilities worth €16.36 Million EUR (≈ $19.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Sensorion SA - Total Liabilities Trend (2011–2024)

This chart illustrates how Sensorion SA's total liabilities have evolved over time, based on quarterly financial data. See Sensorion SA (ALSEN) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Sensorion SA Competitors by Total Liabilities

The table below lists competitors of Sensorion SA ranked by their total liabilities.

Company Country Total Liabilities
Zumtobel Group AG
VI:ZAG
Austria €575.33 Million
Peninsula Energy Ltd
AU:PEN
Australia AU$44.01 Million
Meridian Holdings Inc
NASDAQ:MRDN
USA $61.44 Million
Al-Bad Massuot Yitzhak Ltd
TA:ALBA
Israel ILA1.02 Billion
Clavister Holding AB (publ.)
ST:CLAV
Sweden Skr348.76 Million
EDAP TMS SA
NASDAQ:EDAP
USA $61.96 Million
NH SPAC 2
KQ:206640
Korea ₩37.46 Billion
Uniplus Electronics Co Ltd
TWO:5381
Taiwan NT$2.60 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Sensorion SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sensorion SA (ALSEN) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.90 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sensorion SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sensorion SA (2011–2024)

The table below shows the annual total liabilities of Sensorion SA from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 €17.14 Million
≈ $20.04 Million
+29.57%
2023-12-31 €13.23 Million
≈ $15.46 Million
-22.47%
2022-12-31 €17.06 Million
≈ $19.94 Million
+13.47%
2021-12-31 €15.03 Million
≈ $17.58 Million
+57.85%
2020-12-31 €9.52 Million
≈ $11.13 Million
-61.72%
2019-12-31 €24.88 Million
≈ $29.09 Million
+317.68%
2018-12-31 €5.96 Million
≈ $6.96 Million
+55.06%
2017-12-31 €3.84 Million
≈ $4.49 Million
+17.86%
2016-12-31 €3.26 Million
≈ $3.81 Million
-11.91%
2015-12-31 €3.70 Million
≈ $4.33 Million
+47.11%
2014-12-31 €2.52 Million
≈ $2.94 Million
+7.83%
2013-12-31 €2.33 Million
≈ $2.73 Million
+561.52%
2012-12-31 €352.61K
≈ $412.24K
+67.50%
2011-12-31 €210.51K
≈ $246.11K
--

About Sensorion SA

PA:ALSEN France Biotechnology
Market Cap
$154.93 Million
€132.52 Million EUR
Market Cap Rank
#17611 Global
#261 in France
Share Price
€0.26
Change (1 day)
+11.47%
52-Week Range
€0.23 - €0.70
All Time High
€12.53
About

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more